Global Brucellosis Vaccines Market - 2022-2029

Market Overview

The global brucellosis vaccines market was valued at USD 323.45 million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 4.5% during the forecast period (2022-2029).

The livestock or farm animal's category encompasses cattle, sheep, and goats that are vaccinated to protect against brucellosis diseases. The first dose of this vaccine is given at the age of 4-8 months of calves. It is the most widely used vaccine around the world. The Livestock Vaccine Innovation Fund (LVIF) project collaborates between the J. Craig Venter Institute and the International Livestock Research Institute to promote this vaccine. The LVIF enables improved health of livestock, as farmers' livelihoods depend on livestock. LVIF is an initiative taken by the Bill & Melinda Gates Foundation, Global Affairs Canada, and International Development Research Center (IDRC). It represents a joint investment over five years to reinforce the production, development, and commercialization of innovative vaccines to prevent livestock diseases in sub-Saharan Africa and South and Southeast Asia. The rising prevalence of brucellosis diseases in livestock and the increasing consumption of meat products are some factors that are expected to propel market growth.

Market Dynamics: Initiatives by market players will continue supporting the growth of the market during the forecast period

The market players are taking several initiatives by launching awareness programs in underdeveloped countries to raise awareness about livestock vaccination to maintain animal health and welfare. In December 2018, Boehringer Ingelheim launched the 'LastMile' initiative to focus on crucial animal health challenges by making animal medical resources available in hard-to-reach areas. The initiative targets ruminants, such as sheep, goats, and cattle, and will further expand to poultry. The company started this initiative with support from the Global Alliance for Livestock Veterinary Medicines (GALVmed) and was sponsored by BMGF to bridge gaps in access, availability, and awareness of animal healthcare solutions for smallholder farmers in Africa.

In February 2019, FAO launched a cattle vaccination campaign through collaboration with the Ministry of Fisheries and Livestock. The campaign was intended to address the outbreak of symptomatic anthrax, which has caused the loss of more than 3,000 cattle. The FAO aims to protect nearly 9 million animals from combating increasingly common animal diseases, scaling up from 2017. Around 1,000 community-based animal health workers have been trained and are carrying-out routine check-ups and vaccinating livestock through FAO's Emergency Livestock Response Program. Additionally, the Indian government declared a nearly $1.8 billion livestock vaccination scheme in September 2019 from Mathura, India. This initiative is intended to control livestock diseases, primarily brucellosis and foot and mouth disease (FMD), in the next five years.

Market Segmentation: The cattle segment accounted for the highest share in global brucellosis vaccines market

Cattle contribute a significant share in the brucellosis vaccines market. The market players are continuously offering novel products for the cattle. In September 2018, Boehringer Ingelheim launched a new respiratory vaccine, Bovalto Respi Intranasal, for cattle to protect against viruses Parainfluenza 3 Virus (PI3V) and Bovine Respiratory Syncytial Virus (BRSV). In March 2015, Boehringer Ingelheim launched a new vaccine, Bovela against Bovine Viral Diarrhea (BVD), in Europe for active immunization of cattle against both genotypes of the virus (BVDV-1 and BVDV-2). Besides, Zoetis Inc., in April 2018, expanded its manufacturing and research unit to Suzhou, China, to focus on the vaccines for cattle, pigs, fish, and companion animals.

Based on the treatment, the brucellosis vaccine market has been bifurcated into vaccines and antibiotics. Vaccination plays a considerable role in maintaining the proper health of livestock. The high consumption of meat products globally is further contributing to the livestock vaccine's growth, including the brucellosis vaccines market. Therefore, it contributes a significant share in the development of the brucellosis vaccines market across the globe. Several companies are offering and continuously researching the field of brucellosis vaccine.

Geographical Penetration: North America is the dominating region during the forecast period

North America dominated the global brucellosis vaccines market and is expected to retain its position during the forecast period. The US contributed over XX% to the North American brucellosis vaccines market in 2021. Animal husbandry has been a substantial factor in increasing the demand for vaccination in the region. Biological research is encouraging the development of disease-specific vaccinations for animal welfare.

The Asia Pacific is estimated to grow at a considerable growth rate in the brucellosis vaccines market during the forecast period. This growth can be accredited to the continuous rise in meat consumption and trade in the region, especially in China. China's increasing demand for meat makes it one of the largest markets for animal healthcare products for livestock animals. Such huge stats for animal husbandry are expected to grow the brucellosis vaccines market during the forecast period.

Competitive Landscape:

The Brucellosis vaccines market is fragmented due to multiple companies' availability. Some of the major key players in the market are AbbVie, Inc., AstraZeneca PLC, Bayer AG, BeiGene, CARsgen Therapeutics, CStone Pharmaceuticals Co., Ltd. and GlaxoSmithKline PLC, among others. The key players are adopting various growth strategies, such as acquisitions, product launches, and collaborations, contributing to the growth of the Brucellosis Vaccines market globally. In July 2020, AstraZeneca and Merck & Co., Inc. announced that Lynparza (olaparib) had been approved in the European Union (EU) for patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer. This approval further provides the company with a significant opportunity to sustain a substantial European pancreatic cancer drugs market position. In June 2020, AbbVie collaborated with Jacobio Pharmaceuticals to develop and commercialize SHP2 inhibitors that act on an important node in cancer and immune cells. In January 2022, AbbVie Announced U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for the treatment of non-small cell lung cancer. In October 2021, US FDA approved Roche's Tecentriq as an adjuvant treatment for people with early non-small cell lung cancer. It is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting.

COVID-19 Impact: Negative impact on the global Brucellosis Vaccines market

The outbreak of COVID-19 has certainly impacted the global brucellosis vaccines market. The lockdown has compelled the veterinaries to close their operations, or even if the vets are open, the public was afraid to visit vets for vaccination during the meantime. Besides, the consumption of meat and dairy products has decreased during the outbreak, which, in turn, has impacted the expansion of livestock across the globe. Therefore, the brucellosis vaccines market is expected to foresee a considerable decline in 2020.

The global brucellosis vaccines market report would provide an access to approximately 73 market data tables, 57 figures and 170 pages